The lancet oncology
-
The lancet oncology · Jul 2022
Randomized Controlled Trial Multicenter StudyFulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared to be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status of tumours, as ascertained using assays available at the time. Here, we report updated progression-free survival and overall survival results, and a prespecified examination of the effect of PI3K/AKT/PTEN pathway alterations identified by an expanded genetic testing panel on treatment outcomes. ⋯ AstraZeneca and Cancer Research UK.
-
The lancet oncology · Jul 2022
Multicenter Study Observational StudyEarly detection of hepatocellular carcinoma with methylation and fragmentation signatures of circulating tumour DNA: a prospective, multicentre, case-control, observational study.
Hepatocellular carcinoma is one of the deadliest cancers worldwide. Early detection has been shown to enable more effective treatments, thus decreasing morbidity and mortality. Non-invasive cancer detection via circulating tumour DNA (ctDNA) has emerged as a promising approach to monitor the molecular changes in liver tumour cells. We aimed to use ctDNA methylation and fragmentation signals to develop a blood-based assay for hepatocellular carcinoma early detection, named HcSeer. ⋯ This study was supported by the National Key Research and Development Program of China (grant number 2019YFC1315800).
-
The lancet oncology · Jul 2022
Multicenter StudyOutcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. ⋯ National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.
-
The lancet oncology · Jul 2022
Multicenter StudyEffect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study.
Few studies have evaluated the effect of glucose concentrations on cancer prognosis. We investigated the association between haemoglobin A1c (HbA1c) concentrations and survival in patients with oral squamous cell carcinoma. ⋯ Kaohsiung Chang Gung Memorial Hospital, Taiwan (grant numbers CFRPG8K0131 and CORPG8L0481).
-
The lancet oncology · Jul 2022
Randomized Controlled Trial Multicenter StudyUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer. ⋯ GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche.